Compare ADAM & DCTH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ADAM | DCTH |
|---|---|---|
| Founded | 2003 | 1988 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Computer Software: Prepackaged Software | Medical/Dental Instruments |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 702.0M | 578.4M |
| IPO Year | 2003 | 2015 |
| Metric | ADAM | DCTH |
|---|---|---|
| Price | $6.01 | $14.32 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 7 | 5 |
| Target Price | $11.50 | ★ $24.00 |
| AVG Volume (30 Days) | ★ 1.0M | 262.9K |
| Earning Date | 10-28-2026 | 11-09-2026 |
| Dividend Yield | ★ 18.35% | N/A |
| EPS Growth | ★ 196.49 | 107.53 |
| EPS | N/A | ★ 0.04 |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | $24.61 |
| Revenue Next Year | $8.59 | $24.27 |
| P/E Ratio | ★ $7.53 | $351.75 |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $6.55 | $8.12 |
| 52 Week High | $10.36 | $17.42 |
| Indicator | ADAM | DCTH |
|---|---|---|
| Relative Strength Index (RSI) | 19.31 | 42.11 |
| Support Level | N/A | $14.26 |
| Resistance Level | $9.36 | $16.51 |
| Average True Range (ATR) | 0.31 | 0.53 |
| MACD | -0.09 | -0.01 |
| Stochastic Oscillator | 5.00 | 29.33 |
Adamas Trust Inc is an internally-managed REIT for U.S. federal income tax purposes, in the business of acquiring, investing in, financing, and managing mainly mortgage-related single-family and multi-family residential assets. Its objective is to deliver long-term stable distributions to its stockholders over changing economic conditions through a combination of net interest spread and capital gains from a diversified investment portfolio. The company's investment portfolio includes credit-sensitive single-family and multi-family assets.
Delcath Systems Inc is an oncology company. The company is focused on the treatment of primary and metastatic liver cancers. The firm's product include Melphalan Hydrochloride, Hepzato for Injection along with the Delcath Hepatic Delivery System, or Melphalan/HDS, is a drug and device combination product, designed to administer high-dose chemotherapy to the liver while controlling systemic exposure and associated side effects. The company operates in one reportable segment which includes the research, development, manufacture, and distribution of hepatic delivery systems for use in the treatment of specific conditions. The Company operates its business in the United States and Europe.